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Abstract 
SIRT1 has been considered as a tumor promoter because of its increased expression in 
some types of cancers and its role in inactivating proteins that are involved in tumor sup-
pression and DNA damage repair. However, recent studies demonstrated that SIRT1 levels 
are reduced in some other types of cancers, and that SIRT1 deficiency results in genetic in-
stability and tumorigenesis, while overexpression of SIRT1 attenuates cancer formation in 
mice heterozygous for tumor suppressor p53 or APC. Here, I review these recent findings 
and discuss the possibility that activation of SIRT1 both extends lifespan and inhibits cancer 
formation. 
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Introduction 
Epigenetic modifications of protein, histone, and 
chromatin play an important role in regulating gene 
expression, cancer formation, and lifespan. In bud-
ding yeast, Sir2 is a NAD+-dependent histone deace-
tylase that plays a role in chromatin silencing, lon-
gevity and genomic stability [1, 2]. In mammals, seven 
sirtuin proteins (SIRT1-7) have been found to share 
homology with Sir2 and are suspected to have many 
similar functions as Sir2 [1, 3, 4]. SIRT1, a proto 
member of the sirtuin family, modifies histones 
through deacetylation of K26 in histone H1 (H1K26), 
K9 in histone H3 (H3K9) and K16 in histone H4 
(H4K16). It also deacetylates many non-histone pro-
teins that are involved in cell growth, apoptosis, 
neuronal protection, adaptation to calorie restriction, 
organ metabolism and function, cell senescence, and 
tumorigenesis [1, 3-5]. However, it remains contro-
versial whether SIRT1 acts as a tumor promoter or 
tumor suppressor due to recent controversy over 
SIRT1 regarding: 1) its expression level in human 
cancers; 2) its activity on tumor suppressors and on-
coproteins; 3) its effect on growth arrest, cell death, 
and DNA damage repair; and, finally, 4) its long-term 
impact on lifespan and cancer risk.  
Expression of SIRT1 in cancer 
It has been shown that SIRT1 is significantly 
elevated in human prostate cancer [6], acute myeloid 
leukemia [7], and primary colon cancer [8]. Hida et al. 
examined SIRT1 protein levels in several different 
types of skin cancer by immunohistochemical analysis 
[9]. Overexpression of SIRT1 was frequently observed 
in all kinds of non-melanoma skin cancers including 
squamous cell carcinoma, basal cell carcinoma, Bo-
wen's disease, and actinic keratosis. Based on the 
elevated levels of SIRT1 in cancers, it was hypothe-
sized that SIRT1 serves as a tumor promoter [10]. 
However it does not rule out a possibility that in-
creased expression of SIRT1 is a consequence, rather 
than a cause, of tumorigenesis. In contrast, Wang et al. 
analyzed a public database and found that SIRT1 ex-
pression was reduced in many other types of cancers, 
including glioblastoma, bladder carcinoma, prostate 




corresponding normal tissues [11]. Their further 
analysis of 44 breast cancer and 263 hepatic carcinoma 
cases also revealed reduced expression of SIRT1 in 
these tumors [11]. These data suggest that SIRT1 acts 
as a tumor suppressor rather than a promoter in these 
tissues.  
SIRT1 as a tumor promoter 
The first evidence of SIRT1 as a tumor promoter 
came from experiments showing that SIRT1 physi-
cally interacts with p53 and attenuates p53-mediated 
functions through deacetylation of p53 at its 
C-terminal Lys382 residue [12, 13]. They further 
showed that overexpression of SIRT1 represses 
p53-dependent cell cycle arrest and apoptosis in re-
sponse to DNA damage and oxidative stress. How-
ever, expression of a SIRT1 mutant form that carries a 
point mutation disrupting its deacetyalase activity, 
increases the sensitivity of cells to a stress response 
[12, 13]. More recently, it was shown that inhibition of 
SIRT1 by a specific inhibitor causes p53 hyperacetyla-
tion and increases p53-dependent transcriptional ac-
tivity [14]. In addition, overexpression of SIRT1 epi-
genetically represses expression and/or activity of 
many tumor suppressor genes, and proteins with 
DNA damage repair functions. This includes fork-
head class O transcription factor (FOXO) family 
members (FOXO1, FOXO3a and FOXO4) [15], p73 
[16], RB [17], SFRP1, SFRP2, GATA4, GATA5, CDH1, 
MLH1 [18], Ku70 [19], NBS1 [20], and WRN [21]. 
Consistent with these data, a number of studies 
showed that depletion of SIRT1 by siRNA reduces 
drug resistance and/or induces growth arrest of can-
cer cells in vitro [18, 22-24]. 
On the other front, expression and/or activity of 
SIRT1 are also subjected to regulation by several tu-
mor suppressors. Hypermethylated in cancer-1 
(HIC1) encodes a transcriptional repressor with zinc 
finger motifs and a N-terminal BTB/POZ domain that 
cooperates with p53 to suppress age-dependent de-
velopment of cancer in mice [25]. HIC1 and SIRT1 
form a transcriptional repression complex, which di-
rectly binds to SIRT1 promoter and represses SIRT1 
transcription. In both normal and cancer cells, inacti-
vation of HIC1 results in upregulated SIRT1 expres-
sion, which deacetylates and inactivates p53, allowing 
cells to bypass apoptosis and survive DNA damage 
[26]. Because p53 trans-activates HIC1, the authors 
proposed a circular regulatory loop among HIC1, 
SIRT1, and p53, i.e. HIC1 represses the transcription 
of SIRT1, SIRT1, in turn, deacetylates p53, and p53, 
then, activates HIC1, for modulating p53 activity in 
DNA damage response (DDR), cell cycle progression 
and apoptosis (Fig. 1A). Specifically, the authors 
proposed that in normal situations, actively expressed 
HIC1 represses SIRT1  transcription, thereby main-
taining p53 in an active state in controlling growth 
arrest and apoptosis in response to DNA damage [26]. 
In cells in which proper repair of DNA damage is 
accomplished, subsequent decreased p53 can lead to 
decreased HIC1 and increased SIRT1 expression to 
keep p53 in an inactive state.  However, during the 
course of aging, the HIC1 promoter undergoes hy-
permethylation. As a consequence, upregulation of 
SIRT1 in aging cells due to epigenetic silencing of 
HIC1 might be a double-edged sword that both pro-
motes survival of aging cells and increases cancer risk 
in mammals [26]. 
In addition, two recent studies demonstrated 
that DBC1 (deleted in breast cancer-1), which was 
initially cloned from a region (8p21) homozygously 
deleted in breast cancer, forms a stable complex with 
SIRT1 and inhibits SIRT1 activity, leading to increased 
levels of p53 acetylation and upregulation of 
p53-mediated function. Consistently, knockdown of 
DBC1 by RNA interference (RNAi) promoted 
SIRT1-mediated deacetylation of p53 and inhibited 
p53-mediated apoptosis induced by genotoxic stress. 
These effects were reversed in cells by concomitant 
RNAi-mediated knockdown of endogenous SIRT1 
[27, 28]. These data suggest that increased SIRT1 ex-
pression and/or activity may increase the risk of 
cancer in mammals by inhibiting p53 and potentially 
other tumor suppressor genes (Fig. 1A). 
Genetically engineered mice have provided a 
powerful means to assess gene function in vivo 
[29-31]. However, SIRT1’s role in tumorigenesis could 
not be directly assessed due to embryonic lethality in 
most  Sirt1-/-  embryos [11, 32, 33]. Because SIRT1 
deacetylates and inactivates p53, it was suspected that 
SIRT1 deficiency might activate p53, leading to the 
lethality of mutant mice [33]. However, analysis of 
SIRT1 mutant embryos failed to detect altered ex-
pression p53 downstream genes, while introduction 
of a p53-null mutation into SIRT1 mutant mice failed 
to rescue the embryonic lethality of Sirt1-/- embryos 
[11, 34]. Thus, despite the fact that SIRT1 deacetylates 
p53, SIRT1 does not affect many p53-mediated bio-
logical activities in vivo. Currently, several transgenic 
mouse stains carrying overexpression of SIRT1 have 
been established. Overexpresson of SIRT1 reduces 
energy expenditure, improves metabolism and pre-
vents diabetes in mice, while no tumor formation has 
been reported in these mice [35-37]. Thus, it remains 
elusive whether or not increased levels of SIRT1 can 
enhance cancer risk due to the lack of in vivo data. 
Continuous monitoring of these mice might eventu-





Figure 1. Models illustrating possible functions of SIRT1 in 
tumor promotion or suppression. A. SIRT1 deacetylates 
and inactivates p53, leading to down regulation of 
p53-mediated growth arrest and apoptosis. This may result 
in increased risk of cancer. Transcription and activity of 
SIRT1 are also negatively regulated by many tumor sup-
pressor genes, including DBC1, HIC1, and p53, which may 
regulate SIRT1 through HIC1. B. BRCA1 and resveratrol 
can positively regulate SIRT1 transcription and activity, 
respectively. Increased SIRT1, in turn, inhibits expression 
and/or activity of several oncogenes, leading to reduced cell 
proliferation, increased apoptosis, and tumor suppression. 
C. In response to DNA damage, SIRT1 dissociates from 
highly repetitive DNA and relocalizes to DSBs to promote 
repair and maintain genome integrity. ATM and γH2AX are 
required for the efficient recruitment of SIRT1 to DSBs. 
Moreover, SIRT1 deficiency impaired BRCA1, RAD51 and 
NBS1 foci formation, suggesting direct or indirect interac-
tions of these proteins in the DNA damage foci. SIRT1 
overexpression suppresses the age-related transcriptional 
changes and tumor formation, suggesting a possibility to 
extend lifespan and inhibit tumor formation through acti-
vation of SIRT1. 
 
SIRT1 as a tumor suppressor 
On the other hand, several recent studies have 
provided convincing evidence that SIRT1 serves as a 
tumor suppressor. Firestein et al demonstrated that 
overexpression of SIRT1 in APCmin/+ mice reduces, 
instead of increases, colon cancer formation [38]. The 
data demonstrated that the reduction in tumor de-
velopment is caused by the ability of SIRT1 to deace-
tylate β-catenin and promote cytoplasmic localization 
of the nuclear-localized oncogenic form of β-catenin. 
Their further analysis also uncovered a significant 
inverse correlation between the presence of nuclear 
SIRT1 and the oncogenic form of β-catenin in 81 hu-
man colon tumor specimens analyzed. Ectopic 
over-expression of SIRT1 also greatly reduces cell 
proliferation in a human colon cancer cell line whose 
growth is driven by active β-catenin [38]. An earlier 
study also showed that SIRT1 deacetylates the 
RelA/p65 subunit of NF-κB and sensitizes cells to 
TNFα-induced apoptosis by inhibiting the transacti-
vation potential of the RelA/p65 protein [39]. 
Analyzing published database for SIRT1 expres-
sion, Wang et al. found that SIRT1 expression is much 
lower in the BRCA1-associated breast cancer than 
BRCA1-wildtype breast cancer in human [40]. They 
further showed that BRCA1 binds to the SIRT1 pro-
moter and positively regulates SIRT1 gene expression 
at both the mRNA and protein level, and that BRCA1 
deficiency causes reduced SIRT1 levels, which may be 
responsible for the malignant transformation of 
BRCA1 mutant cells. Consistently, restoration of 
SIRT1 levels in BRCA1 mutant cancer cells inhibited 
proliferation of these cells in vitro and tumor forma-
tion in vivo when the cells were implanted into nude 
mice. In addition, resveratrol, which activates SIRT1 
deacetylase activity [41], induced apoptosis in these 
cells and inhibited tumor formation [40]. These data 
suggest that SIRT1 not only acts as a tumor suppres-
sor in the context of BRCA1 deficiency, but also that a 
SIRT1 activator, such as resveratrol, could serve as an 
excellent strategy for targeted therapy for 
BRCA1-associated breast cancer. To illustrate the 
molecular mechanism underlying how activated 
SIRT1 triggers cell death, the researchers demon-
strated that SIRT1 negatively regulates expression of 
Survivin, which encodes an anti-apoptotic protein, by 
deacetylating H3K9 within the promoter of Survivin 
[40]. Altogether, these data suggest that SIRT1 medi-
ates BRCA1 signaling and inhibits tumor growth 
through repressing transcription of oncogenes or ac-
tivity of oncoproteins (Fig. 1B).  
Two recent investigations reported that SIRT1 
plays an important role in DNA damage repair and in 
maintaining genome integrity. Analyzing 
SIRT1-deficient mice, Wang et al. found that Sirt1-/- 
embryos die at middle gestation stages, displaying 




chromosome condensation, impaired heterochro-
matin formation, and abnormal mitosis [11]. Sirt1-/- 
cells displayed chromosome aneuploidy and struc-
tural aberrations, conceivably originated from the 
continuous division of abnormal mitosis. SIRT1 defi-
ciency also causes reduced ability to repair 
DNA-double strand breaks (DSBs), radiation sensi-
tivity, and impaired DDRs characterized by dimin-
ished γH2AX, BRCA1, RAD51 and NBS1 foci forma-
tion upon γ-irradiation. Thus, SIRT1 may play a role 
in recruiting these proteins to DNA damage sites. Of 
note, Western blot analysis detected reduced level of 
γH2AX, but not that of BRCA1, RAD51 and NBS1 
upon DNA damage in SIRT1 mutant cells compared 
with wild type cells. To assess whether the reduced 
γH2AX levels/foci formation is a direct consequence 
of SIRT1 loss, the researchers transfected 
SIRT1-deficient cells with a SIRT1 expression vector, 
and the data indicated that the SIRT1-reconstituted 
Sirt1-/- cells contained relatively equal numbers of 
γH2AX foci compared with wild type controls upon 
γ-irradiation [11]. These observations suggest that 
γH2AX plays an important role in mediating functions 
of SIRT1 in DNA damage foci formation and DNA 
damage repair. 
As mentioned earlier that introduction of a 
p53-null mutation into Sirt1-/- mice does not repress 
embryonic lethality. However, Sirt1+/-;p53+/-  mice 
started to develop spontaneous tumors in multiple 
organs from about 5 months of age, and tumor inci-
dence reached about 76% by 20 months of age, while 
only 2 out of 21 Sirt1+/- mice and 3 out of 22 p53+/- mice 
developed tumors during the same period of time. 
Chromosome spreads and spectral karyotyping 
analysis of primary tumors revealed extensive ane-
uploidy and chromosomal aberrations, notably 
translocations, chromosome breaks, deletions, end 
fusions, and dicentric chromosomes. These results 
suggest that severe genetic instability could be one of 
the causes for spontaneous tumorigenesis in SIRT1 
and p53 double-heterozygous animals. Interestingly, 
most tumors developed in the Sirt1+/-;p53+/- mice lost 
the remaining wild-type allele of p53 yet retained a 
functional wild-type Sirt1 allele. Accordingly, ad-
ministration of resveratrol to these mice significantly 
reduced tumor formation [11]. These data demon-
strate that SIRT1 plays an important role in main-
taining genome integrity and acts as a haploinsuffi-
cient tumor suppressor in mice (Fig. 1C). 
Using mouse embryonic stem cells, Oberdoerffer 
et al demonstrated that SIRT1 binds to highly repeti-
tive DNA and contributes to the silencing of major 
satellite repeats [42]. In response to oxidative DNA 
damage, SIRT1 dissociates from its original loci and 
relocalizes to DSBs to promote repair and maintain 
genome integrity. Their data indicated that the effi-
cient recruitment of SIRT1 to DSBs requires DNA 
damage signalling through ATM and H2AX. Without 
SIRT1, recruitment of RAD51 and NBS1 to DSBs was 
delayed and strongly reduced, thus highlighting a key 
role of SIRT1 in the DNA damage repair process. The 
researchers further showed that SIRT1 inhibits a 
functionally diverse set of genes that are dereprssed 
by oxidative stress. Interestingly, more than 
two-thirds of these SIRT1-repressed genes are over 
expressed in 30 months old mice compared with 5 
months old mice. Transcripts of major satellite repeat 
are also increased significantly in the aged mice [42]. 
To investigate the role of SIRT1 in tumorigenesis, 
the authors crossed a transgenic strain carrying 
overexpression of SIRT1 with p53+/- mice and found 
that SIRT1 overexression in p53+/- mice led to a de-
creased incidence of thymic lymphoma and increased 
survival following exposure to γ-irradiation. A similar 
effect was also observed in p53+/- m i c e  t h a t  w e r e  
treated with resveratrol, which activates SIRT1 [42]. 
These data provide strong evidence that SIRT1 serves 
as a tumor suppressor through its role in DDR and 
DSB repair that are essential for maintaining genome 
integrity. Because SIRT1 overexpression also sup-
presses the age-related transcriptional changes, it 
suggests that activation of SIRT1 might both extend 
lifespan and reduce cancer risk (Fig. 1C). 
Perspective 
The controversy over whether SIRT1 serves as a 
tumor promoter or a tumor suppressor has not been 
completely solved and the discussion will likely con-
tinue. One of the major concerns that SIRT1 activation 
may increase cancer risk comes from the observation 
that SIRT1 deacetylates and inactivates p53, and other 
tumor suppressors [26-28]. However, it is also known 
that p53 positively regulates SIRT1 transcription and 
loss of p53 impairs SIRT1 induction [43]. Thus, 
through a negative feedback loop, p53 inactivation 
can, in theory, reduce expression level of SIRT1, 
thereby increasing p53 activity. Similar negative 
feedback loops are also found in FOXO3a [43], FOXL2 
[44] and E2F1 [45], which act as tumor suppressors 
under certain circumstances. Thus, like p53, the ac-
tivities of these proteins are not easily inactivated by 
SIRT1 due to this negative feedback mechanism. De-
spite the lack of in vivo evidence that activation of 
SIRT1 may increase cancer risk, however, it remains 
possible that SIRT1 plays dual functions in different 
tissue contexts depending on the spatial and temporal 




stream targets and factors that regulate SIRT1. Further 
studies are needed to provide a conclusive answer. 
For cancer therapy, irrespective of SIRT1’s role 
as a tumor suppressor or promoter, it is important to 
identify endogenous genes or small chemicals that 
inhibit or activate SIRT1. Because Sir2 plays an essen-
tial role in lifespan extension in yeast, C. elegans and 
Drosophila [1], investigating whether SIRT1 has the 
same function in mammals is important. Aging has 
been considered as the most potent carcinogen for 
cancer, as cancer incidence is quickly elevated in the 
aging population [46]. It is of great interest to define 
the conditions, in which the activation of SIRT1 can 
both extend lifespan and inhibits tumor formation. In 
C. elegans, mutations that increase the lifespan can 
also inhibit tumor growth [47]. In animal models, ca-
loric restriction, which activates SIRT1, extends life-
span and is also highly protective against cancer [19, 
48-50]. 
Then, can direct activation of SIRT1 both extend 
lifespan and reduce cancer risk? Several lines of evi-
dence suggest that it is possible. First, it has been 
shown that activation of SIRT1 by a low dose of die-
tary resveratrol partially mimics caloric restriction 
and retards aging parameters in mice [51]. Similarly, 
SRT1720, a more potent and specific agonist in acti-
vating SIRT1 than resveratrol [52], mimics low energy 
levels and protects against diet-induced metabolic 
disorders by enhancing fat oxidation [49]. Secondly, 
cancer is a metabolic disease. It has been demon-
strated that aggressive cancer cells have a high rate of 
energy-consuming anabolic processes that promote 
the synthesis of lipids, proteins, and DNA, while de-
creased energy expenditure prevents tumorigenesis 
[53, 54]. Finally, as illustrated above that SIRT1 over-
expression suppresses the age-related transcriptional 
changes and reduces formation of colon cancer in 
APC+/min mice [38], BRCA1-associated mammary 
cancer [40], spontaneous cancers in multiple tissues of 
Sirt1+/-;p53+/- mice [11], and γ-irradiation induced 
lymphoma in p53+/- mice [42]. Thus, through im-
proving metabolic conditions by increasing SIRT1 
activity, it is possible to both extend lifespan and re-
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